MRK Aug 2024 150.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:58PM EDT. Market open.
Loading interactive chart...
- Investor's Business Daily
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.
- Simply Wall St.
Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?
Merck's (NYSE:MRK) stock is up by 2.7% over the past week. Given that the markets usually pay for the long-term...
- Business Wire
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024--The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (TSE: 4568) and Merck’s (known as MSD outside of the United States and Canada) (NYSE: MRK) patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with tw
© 2024 Yahoo. All rights reserved.